melanoma

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to…

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® in a Phase 1b Clinical Trial in Melanoma

The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top